Guillain-Barre Syndrome

Autoimmune MONDO:0016218 Pathograph 7 Autoimmune Disease Peripheral Neuropathy

An acute immune-mediated polyradiculoneuropathy characterized by rapidly progressive symmetric weakness and areflexia. Typically preceded by infection, with molecular mimicry between pathogen antigens and peripheral nerve gangliosides driving the autoimmune response.

Ask OpenScientist

Ask a research question about Guillain-Barre Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

4
Pathophys.
8
Phenotypes
1
Gaps
7
Pathograph
5
Medical Actions
4
Subtypes
1
Trials
14
References
2
Deep Research
🏷

Classifications

Harrison's Chapter
NEUROLOGIC IMMUNE_RHEUMATOLOGIC
◆

Subtypes

4
AIDP MONDO:0020347
Demyelinating GBS subtype in which immune-mediated injury targets peripheral myelin and Schwann-cell membranes; it is the most common form in North America and Europe.
Show evidence (1 reference)
DOI:10.1186/s43161-024-00258-8 SUPPORT Human Clinical
"This systematic review aims to elucidate the autoimmune mechanisms underlying the various subtypes of GBS, including acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), and Miller Fisher syndrome (MFS)."
The systematic review lists AIDP as a major GBS subtype.
AMAN MONDO:0020349
Axonal motor subtype associated with antiganglioside antibodies and Campylobacter jejuni molecular mimicry, with relative sensory sparing.
Show evidence (1 reference)
DOI:10.1186/s43161-024-00258-8 SUPPORT Human Clinical
"This systematic review aims to elucidate the autoimmune mechanisms underlying the various subtypes of GBS, including acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), and Miller Fisher syndrome (MFS)."
The systematic review lists AMAN as a major GBS subtype.
AMSAN MONDO:0020348
Axonal GBS subtype with both motor and sensory nerve involvement, typically more severe than purely motor AMAN.
Show evidence (1 reference)
DOI:10.1186/s43161-024-00258-8 SUPPORT Human Clinical
"This systematic review aims to elucidate the autoimmune mechanisms underlying the various subtypes of GBS, including acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), and Miller Fisher syndrome (MFS)."
The systematic review lists AMSAN as a major GBS subtype.
Miller Fisher Syndrome MONDO:0005851
Regional GBS subtype classically associated with ophthalmoplegia, ataxia, and areflexia, and frequently linked to anti-GQ1b antibodies.
Show evidence (1 reference)
DOI:10.1186/s43161-024-00258-8 SUPPORT Human Clinical
"This systematic review aims to elucidate the autoimmune mechanisms underlying the various subtypes of GBS, including acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), and Miller Fisher syndrome (MFS)."
The systematic review lists Miller Fisher syndrome as a major GBS subtype.
?

Discussions and Knowledge Gaps

1
Bickerstaff Brainstem Encephalitis (BBE) is a central nervous system variant of the anti-GQ1b antibody syndrome spectrum, presenting with ophthalmoplegia, ataxia, and altered consciousness. However, approximately one-third of clinically defined BBE cases are seronegative for anti-GQ1b antibodies, suggesting alternative immune mechanisms beyond anti-GQ1b pathogenic cascades. What mechanisms drive seronegative BBE? How do alternative immune pathways (beyond anti-GQ1b) drive complement-mediated neural damage in the brainstem?
KNOWLEDGE GAP OPEN seronegative_bbe_mechanisms
Attached to
pathophysiology#Molecular Mimicry and Antiganglioside Antibodies pathophysiology#Complement-Mediated Nerve Damage
BBE sits within the anti-GQ1b antibody syndrome spectrum but shows significant clinical and serological overlap with Miller Fisher syndrome and GBS. The discovery of seronegative BBE cases indicates that the canonical anti-GQ1b IgG mechanism does not explain all pathophysiology in this disease variant. Understanding alternative immune mechanisms in seronegative cases is critical for diagnosis and therapeutic targeting.
Show evidence (2 references)
PMID:42093930 SUPPORT Human Clinical
"Bickerstaff Brainstem Encephalitis (BBE) is a rare, post-infectious autoimmune disorder characterized by ophthalmoplegia, ataxia, and altered consciousness. Its significant clinical and serological overlap with Miller Fisher syndrome (MFS) and Guillain-Barré syndrome (GBS) creates diagnostic..."
Establishes BBE as part of the anti-GQ1b spectrum with clinical overlap to MFS and GBS.
PMID:42093930 SUPPORT Human Clinical
"Approximately one-third of clinically defined BBE cases are seronegative, suggesting alternative mechanisms."
Documents the prevalence of seronegative BBE and explicitly frames this as a mechanism-seeking question.
⚙

Pathophysiology

4
Molecular Mimicry and Antiganglioside Antibodies
Antibodies against bacterial lipooligosaccharides (especially from Campylobacter jejuni) cross-react with gangliosides on peripheral nerves. Anti-GM1, anti-GD1a, and anti-GQ1b antibodies are associated with specific clinical subtypes.
Immunoglobulin Production GO:0002377
Show evidence (2 references)
PMID:24000328 SUPPORT
"Molecular mimicry between sialylated lipooligosaccharide structures on the cell envelope of these bacteria and ganglioside epitopes on the human nerves that generates cross-reactive immune response results in autoimmune-driven nerve damage."
Demonstrates the molecular mimicry mechanism where C. jejuni lipooligosaccharides resemble nerve gangliosides, leading to cross-reactive antibodies that attack peripheral nerves.
PMID:37108447 SUPPORT
"The presence of specific anti-glycoconjugate antibodies indicates an underlying process of molecular mimicry and sometimes assists in the classification of these disorders."
Confirms that anti-ganglioside antibodies in GBS result from molecular mimicry and help classify disease subtypes.
Complement-Mediated Nerve Damage
Antibody binding activates complement cascade, leading to membrane attack complex deposition on Schwann cells and nodes of Ranvier. This causes demyelination in AIDP or axonal damage in AMAN/AMSAN variants.
Schwann Cell CL:0002573
Complement Activation GO:0006956
Show evidence (2 references)
PMID:10355667 PARTIAL
"These data indicate that anti-ganglioside antibodies can diffuse into a desheathed nerve, bind to nodes of Ranvier and fix complement in vitro without resulting in any overt physiological deterioration of the nerve over 4-6 h."
Demonstrates that anti-ganglioside antibodies bind nodes of Ranvier and activate complement cascade, establishing the complement-mediated mechanism of nerve damage.
PMID:8619548 SUPPORT
"Many fibers had a rim of the complement activation marker C3d and the terminal complement complex neoantigen C5b-9 along the outer surface of the Schwann cells."
Immunocytochemistry evidence showing C3d and C5b-9 membrane attack complex deposition on Schwann cell surfaces in AIDP, confirming complement-mediated pathology.
Macrophage-Mediated Demyelination
In AIDP, macrophages infiltrate peripheral nerves and strip myelin from axons. T cells may also contribute to the inflammatory milieu and tissue damage.
Macrophage CL:0000235
Inflammatory Response GO:0006954
Show evidence (2 references)
PMID:37108447 SUPPORT
"The immunological mechanisms, which include macrophage infiltration, inflammation and proliferation of Schwann cells, result in variable degrees of demyelination and axonal degeneration."
Describes macrophage infiltration as a key immunological mechanism leading to demyelination and axonal degeneration in immune-mediated neuropathies including GBS.
PMID:8619548 SUPPORT
"Vesicular degeneration was seen before the invasion of macrophages into the myelin, and was the predominant change in the subject with symptoms for 3 days."
Shows the temporal sequence of pathology in AIDP, with macrophage invasion into myelin following initial complement-mediated damage.
Seronegative and Alternative Immune Mechanisms in Anti-GQ1b Syndromes
The anti-GQ1b antibody syndrome spectrum encompasses Bickerstaff Brainstem Encephalitis (BBE), Miller Fisher Syndrome (MFS), and related disorders. Approximately one-third of clinically defined BBE cases are seronegative for anti-GQ1b antibodies, indicating alternative immune pathways beyond the canonical anti-GQ1b IgG-mediated complement-dependent pathway. Seronegative cases suggest additional mechanisms driving complement-mediated damage to ganglioside-rich neural structures.
Complement Activation GO:0006956
Downstream
Complement-Mediated Nerve Damage
Show evidence (2 references)
PMID:42093930 SUPPORT Human Clinical
"Approximately one-third of clinically defined BBE cases are seronegative, suggesting alternative mechanisms."
The review identifies seronegative BBE as a key gap in understanding the anti-GQ1b antibody syndrome spectrum, highlighting that mechanisms beyond anti-GQ1b IgG antibodies drive some BBE cases.
PMID:42093930 SUPPORT Human Clinical
"Pathogenesis is primarily driven by anti-GQ1b IgG antibodies, generated following infection via molecular mimicry, which trigger complement-mediated damage to ganglioside-rich neural structures. The clinical presentation ranges from purely peripheral deficits (MFS) to severe central nervous..."
Confirms the spectrum nature of anti-GQ1b syndromes and establishes that complement-mediated damage is a unifying mechanism across the spectrum, suggesting that seronegative cases may involve alternative triggers of the same complement-dependent pathway.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Guillain-Barre Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

8
Limbs 1
Limb Weakness VERY_FREQUENT Limb muscle weakness HP:0003690
Ascending, symmetric
Show evidence (1 reference)
PMID:33603872 SUPPORT Human Clinical
"Guillain-Barré syndrome is an acute immune-mediated disease that affects the peripheral nervous system, with progressive motor deficit in the limbs"
Progressive motor deficit in the limbs supports limb weakness as a core GBS phenotype.
Nervous System 4
Areflexia VERY_FREQUENT Areflexia HP:0001284
Universal finding
Show evidence (1 reference)
PMID:33603872 SUPPORT Human Clinical
"GBS affects the peripheral nervous system and is characterized by progressive motor deficit in the limbs with ascending sensory deficits, involvement of muscles innervated by the cranial nerves, reduction or abolition of the deep tendon reflexes, and possible impairment of the autonomic nervous system"
The review explicitly describes reduction or abolition of deep tendon reflexes as part of the GBS clinical syndrome.
Autonomic Dysfunction FREQUENT Abnormal autonomic nervous system physiology HP:0012332
Includes urinary retention and other autonomic impairment, especially in axonal variants.
Show evidence (1 reference)
PMID:33603872 SUPPORT Human Clinical
"Autonomic impairment is common in GBS, especially in cases where respiratory dysfunction is present, as happened with our patient (2). Urinary dysfunction is one manifestation and has been reported in 50% of patients with axonal GBS, more frequently than in classic GBS (21%), but the underlying..."
The review documents common autonomic impairment in GBS and quantifies urinary dysfunction in axonal and classic GBS, supporting an autonomic dysfunction phenotype.
Paresthesia FREQUENT Paresthesia HP:0003401
Sensory symptoms often precede weakness
Show evidence (1 reference)
DOI:10.3389/fneur.2024.1368706 SUPPORT Human Clinical
"Postoperative sedation, intubation, and restraint use make the diagnosis of GBS difficult, as the onset of symptoms of weakness or numbness in those contexts are not obvious."
The review identifies numbness as a presenting sensory symptom that can accompany GBS weakness.
Cranial nerve involvement Cranial nerve paralysis HP:0006824
Show evidence (1 reference)
PMID:37814552 SUPPORT Human Clinical
"patients may have cranial nerve involvement, respiratory insufficiency, autonomic dysfunction and pain"
The EAN/PNS guideline lists cranial nerve involvement among GBS features.
Respiratory 1
Respiratory Failure FREQUENT Respiratory insufficiency HP:0002093
May require mechanical ventilation
Show evidence (1 reference)
DOI:10.1038/s41582-019-0250-9 SUPPORT
"The ten steps then cover early recognition and diagnosis of GBS, admission to the intensive care unit, treatment indication and selection, monitoring and treatment of disease progression, prediction of clinical course and outcome, and management of complications and sequelae."
The guideline includes ICU admission and monitoring for disease progression, consistent with the need to detect and manage respiratory failure in severe GBS.
Constitutional 1
Pain Pain HP:0012531
Show evidence (1 reference)
PMID:37814552 SUPPORT Human Clinical
"patients may have cranial nerve involvement, respiratory insufficiency, autonomic dysfunction and pain"
The EAN/PNS guideline lists pain among GBS features.
Other 1
Distal sensory impairment Distal sensory impairment HP:0002936
Show evidence (1 reference)
PMID:39058828 SUPPORT Human Clinical
"acute onset ascending paralysis and sensory abnormalities"
This review characterizes GBS by acute onset ascending paralysis and sensory abnormalities.
💊

Medical Actions

5
IVIG
First-line immunotherapy, equally effective as plasmapheresis.
Mechanism Target:
INHIBITS Molecular Mimicry and Antiganglioside Antibodies — IVIG saturates Fc receptors, neutralizes complement activation, and modulates antiganglioside antibody function, reducing antibody-mediated damage to peripheral nerve myelin and axonal membranes.
INHIBITS Complement-Mediated Nerve Damage — IVIG inhibits complement activation pathways and blocks MAC formation, limiting complement-driven destruction of Schwann cell membranes and nodes of Ranvier.
Show evidence (1 reference)
PMID:17217855 SUPPORT Human Clinical
"Meta-analyses show efficacy of plasmapheresis and immunoglobulin therapy, but not corticosteroids, in hastening recovery."
The review summarizes meta-analysis evidence supporting immunoglobulin therapy for GBS recovery.
Plasmapheresis
Removes pathogenic antibodies; alternative to IVIG.
Mechanism Target:
INHIBITS Molecular Mimicry and Antiganglioside Antibodies — Plasmapheresis physically removes circulating antiganglioside antibodies (anti-GM1, anti-GD1b, anti-GQ1b) from the blood, acutely reducing the antibody burden targeting peripheral nerve components.
Show evidence (1 reference)
PMID:17217855 SUPPORT Human Clinical
"Meta-analyses show efficacy of plasmapheresis and immunoglobulin therapy, but not corticosteroids, in hastening recovery."
The review explicitly names plasmapheresis as an evidence-supported GBS treatment.
Supportive Care
ICU monitoring, mechanical ventilation if needed.
Show evidence (1 reference)
DOI:10.1038/s41582-019-0250-9 SUPPORT
"The ten steps then cover early recognition and diagnosis of GBS, admission to the intensive care unit, treatment indication and selection, monitoring and treatment of disease progression, prediction of clinical course and outcome, and management of complications and sequelae."
ICU admission, monitoring, and complication management support the modeled supportive-care treatment entry.
Physical Therapy
Rehabilitation during recovery phase.
Show evidence (1 reference)
PMID:25402491 SUPPORT
"Patients with polyneuropathies have both physical and cognitive disabilities that are amenable to change with rehabilitation, resulting in significant reduction in on-going care-costs, especially for highly dependent patients."
The rehabilitation cohort supports physical therapy and rehabilitation as part of GBS recovery care.
Eculizumab
Action: complement 5 inhibitor agent therapy MAXO:0001483
Agent: Eculizumab NCIT:C48386
Investigational complement C5 inhibitor add-on to IVIG evaluated in severe GBS; the phase 3 trial did not meet its primary efficacy endpoint.
Mechanism Target:
INHIBITS Complement-Mediated Nerve Damage — Eculizumab blocks complement C5 cleavage, preventing MAC assembly at the node of Ranvier and paranodal membrane, the primary target of complement-mediated axonal injury in the AMAN and AMSAN subtypes of GBS.
Target Phenotypes: Limb muscle weakness HP:0003690
Show evidence (1 reference)
DOI:10.1111/jns.12646 PARTIAL Human Clinical
"Although well tolerated, eculizumab treatment did not show significant effects on motor function recovery compared to placebo in patients with GBS."
The phase 3 trial supports eculizumab as a studied complement-directed therapy in severe GBS, while showing no significant motor recovery benefit.
🌍

Environmental Factors

3
Campylobacter jejuni Infection
Most common preceding infection
Show evidence (1 reference)
PMID:24000328 SUPPORT
"Thus, C. jejuni is now considered as a major triggering agent of GBS. Molecular mimicry between sialylated lipooligosaccharide structures on the cell envelope of these bacteria and ganglioside epitopes on the human nerves that generates cross-reactive immune response results in autoimmune-driven..."
Establishes C. jejuni as the major triggering infection for GBS through molecular mimicry mechanism between bacterial lipooligosaccharides and nerve gangliosides.
Cytomegalovirus Infection
Associated with sensory GBS
Show evidence (1 reference)
PMID:33603872 SUPPORT Human Clinical
"The most frequent pathogens involved are C. jejuni, cytomegalovirus (CMV), Epstein-Barr virus (EBV), Zika, post-flu or other events involving immunization with vaccines such as rabies vaccines (27,28), surgery and anesthesia (5)."
The review identifies cytomegalovirus as a major antecedent infection in GBS.
Zika Virus Infection
Associated with outbreaks
Show evidence (1 reference)
DOI:10.1038/s41582-019-0250-9 SUPPORT
"The incidence of GBS can therefore increase during outbreaks of infectious diseases, as was seen during the Zika virus epidemics in 2013 in French Polynesia and 2015 in Latin America."
This guideline review links Zika outbreaks with increased GBS incidence.
🔬

Biochemical Markers

3
CSF Protein (Elevated)
Context: Albuminocytologic dissociation characteristic
Show evidence (1 reference)
PMID:37076309 SUPPORT Human Clinical
"Albuminocytologic dissociation (ACD) was defined as an increased protein level (>0.45 g/L) in the absence of elevated white cell count (<50 cells/μL)."
This large IGOS CSF study defines albuminocytologic dissociation as elevated CSF protein without elevated white-cell count, matching the modeled biochemical finding.
Neurofilament Light Chain (Elevated)
Context: Plasma and CSF axonal injury biomarker in immune-mediated neuropathy
Show evidence (1 reference)
DOI:10.69622/28457924.v1 SUPPORT Human Clinical
"In GBS, CIDP, and PDN, levels of NfL were elevated in both plasma and CSF, whereas in patients with MMN the levels of NfL were elevated only in plasma."
The biomarker study supports neurofilament light chain elevation as a separate GBS-associated biomarker rather than as evidence for total CSF protein.
Antiganglioside Antibodies (Variable)
Context: GM1, GD1a, GQ1b depending on subtype
Show evidence (1 reference)
DOI:10.1186/s43161-024-00258-8 SUPPORT
"Key findings indicate that specific autoantibodies, such as anti-GM1 and anti-GQ1b, are associated with distinct subtypes of GBS, contributing to the disease’s heterogeneity."
The review directly supports antiganglioside antibody variability across GBS subtypes.
🔬

Clinical Trials

1
NCT04752566 PHASE_III COMPLETED
Phase 3 multicenter, double-blind, randomized, placebo-controlled trial of eculizumab add-on therapy to IVIG in severe Guillain-Barre syndrome; the primary endpoint was not achieved.
Target Phenotypes: Limb muscle weakness HP:0003690
Show evidence (2 references)
clinicaltrials:NCT04752566 SUPPORT Human Clinical
"This is a Phase 3, prospective, multicenter, placebo controlled, double blind, randomized study to investigate the efficacy and safety of eculizumab in participants with severe GBS"
The ClinicalTrials.gov summary supports the existence and design of the phase 3 eculizumab trial in severe GBS.
DOI:10.1111/jns.12646 PARTIAL Human Clinical
"Primary endpoint was not achieved (hazard ratio, 0.9; 95% CI, 0.45–1.97; p = .89)."
The published phase 3 report is relevant to severe GBS treatment but did not demonstrate statistically significant primary efficacy.
{ }

Source YAML

click to show 
name: Guillain-Barre Syndrome
creation_date: '2025-12-19T01:12:52Z'
updated_date: '2026-05-17T01:44:31Z'
category: Autoimmune
parents:
- Autoimmune Disease
- Peripheral Neuropathy
disease_term:
  preferred_term: Guillain-Barre Syndrome
  term:
    id: MONDO:0016218
    label: Guillain-Barre syndrome
description: >-
  An acute immune-mediated polyradiculoneuropathy characterized by rapidly
  progressive symmetric weakness and areflexia. Typically preceded by infection,
  with molecular mimicry between pathogen antigens and peripheral nerve
  gangliosides driving the autoimmune response.
has_subtypes:
- name: Acute Inflammatory Demyelinating Polyradiculoneuropathy
  display_name: AIDP
  description: >-
    Demyelinating GBS subtype in which immune-mediated injury targets peripheral
    myelin and Schwann-cell membranes; it is the most common form in North
    America and Europe.
  subtype_term:
    preferred_term: acute inflammatory demyelinating polyradiculoneuropathy
    term:
      id: MONDO:0020347
      label: acute inflammatory demyelinating polyradiculoneuropathy
  evidence:
  - reference: DOI:10.1186/s43161-024-00258-8
    reference_title: "Autoimmune mechanisms in Guillain-Barré syndrome subtypes: a systematic review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This systematic review aims to elucidate the autoimmune mechanisms
      underlying the various subtypes of GBS, including acute inflammatory
      demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy
      (AMAN), acute motor and sensory axonal neuropathy (AMSAN), and Miller
      Fisher syndrome (MFS).
    explanation: >-
      The systematic review lists AIDP as a major GBS subtype.
- name: Acute Motor Axonal Neuropathy
  display_name: AMAN
  description: >-
    Axonal motor subtype associated with antiganglioside antibodies and
    Campylobacter jejuni molecular mimicry, with relative sensory sparing.
  subtype_term:
    preferred_term: acute motor axonal neuropathy
    term:
      id: MONDO:0020349
      label: acute motor axonal neuropathy
  evidence:
  - reference: DOI:10.1186/s43161-024-00258-8
    reference_title: "Autoimmune mechanisms in Guillain-Barré syndrome subtypes: a systematic review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This systematic review aims to elucidate the autoimmune mechanisms
      underlying the various subtypes of GBS, including acute inflammatory
      demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy
      (AMAN), acute motor and sensory axonal neuropathy (AMSAN), and Miller
      Fisher syndrome (MFS).
    explanation: >-
      The systematic review lists AMAN as a major GBS subtype.
- name: Acute Motor and Sensory Axonal Neuropathy
  display_name: AMSAN
  description: >-
    Axonal GBS subtype with both motor and sensory nerve involvement, typically
    more severe than purely motor AMAN.
  subtype_term:
    preferred_term: acute motor and sensory axonal neuropathy
    term:
      id: MONDO:0020348
      label: acute motor and sensory axonal neuropathy
  evidence:
  - reference: DOI:10.1186/s43161-024-00258-8
    reference_title: "Autoimmune mechanisms in Guillain-Barré syndrome subtypes: a systematic review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This systematic review aims to elucidate the autoimmune mechanisms
      underlying the various subtypes of GBS, including acute inflammatory
      demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy
      (AMAN), acute motor and sensory axonal neuropathy (AMSAN), and Miller
      Fisher syndrome (MFS).
    explanation: >-
      The systematic review lists AMSAN as a major GBS subtype.
- name: Miller Fisher Syndrome
  description: >-
    Regional GBS subtype classically associated with ophthalmoplegia, ataxia,
    and areflexia, and frequently linked to anti-GQ1b antibodies.
  subtype_term:
    preferred_term: Miller Fisher syndrome
    term:
      id: MONDO:0005851
      label: Miller Fisher syndrome
  evidence:
  - reference: DOI:10.1186/s43161-024-00258-8
    reference_title: "Autoimmune mechanisms in Guillain-Barré syndrome subtypes: a systematic review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This systematic review aims to elucidate the autoimmune mechanisms
      underlying the various subtypes of GBS, including acute inflammatory
      demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy
      (AMAN), acute motor and sensory axonal neuropathy (AMSAN), and Miller
      Fisher syndrome (MFS).
    explanation: >-
      The systematic review lists Miller Fisher syndrome as a major GBS subtype.
discussions:
- discussion_id: seronegative_bbe_mechanisms
  prompt: >-
    Bickerstaff Brainstem Encephalitis (BBE) is a central nervous system variant
    of the anti-GQ1b antibody syndrome spectrum, presenting with ophthalmoplegia,
    ataxia, and altered consciousness. However, approximately one-third of
    clinically defined BBE cases are seronegative for anti-GQ1b antibodies,
    suggesting alternative immune mechanisms beyond anti-GQ1b pathogenic cascades.
    What mechanisms drive seronegative BBE? How do alternative immune pathways
    (beyond anti-GQ1b) drive complement-mediated neural damage in the brainstem?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Molecular Mimicry and Antiganglioside Antibodies
  - pathophysiology#Complement-Mediated Nerve Damage
  rationale: >-
    BBE sits within the anti-GQ1b antibody syndrome spectrum but shows significant
    clinical and serological overlap with Miller Fisher syndrome and GBS. The
    discovery of seronegative BBE cases indicates that the canonical anti-GQ1b
    IgG mechanism does not explain all pathophysiology in this disease variant.
    Understanding alternative immune mechanisms in seronegative cases is critical
    for diagnosis and therapeutic targeting.
  evidence:
  - reference: PMID:42093930
    reference_title: "A unified spectrum model for the anti-GQ1b antibody syndromes: from pathophysiology to a new diagnostic framework."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bickerstaff Brainstem Encephalitis (BBE) is a rare, post-infectious
      autoimmune disorder characterized by ophthalmoplegia, ataxia, and altered
      consciousness. Its significant clinical and serological overlap with Miller
      Fisher syndrome (MFS) and Guillain-Barré syndrome (GBS) creates diagnostic
      challenges, particularly in atypical or seronegative presentations.
    explanation: >-
      Establishes BBE as part of the anti-GQ1b spectrum with clinical overlap to
      MFS and GBS.
  - reference: PMID:42093930
    reference_title: "A unified spectrum model for the anti-GQ1b antibody syndromes: from pathophysiology to a new diagnostic framework."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Approximately one-third of clinically defined BBE cases are seronegative,
      suggesting alternative mechanisms.
    explanation: >-
      Documents the prevalence of seronegative BBE and explicitly frames this as
      a mechanism-seeking question.
pathophysiology:
- name: Molecular Mimicry and Antiganglioside Antibodies
  description: >-
    Antibodies against bacterial lipooligosaccharides (especially from
    Campylobacter jejuni) cross-react with gangliosides on peripheral nerves.
    Anti-GM1, anti-GD1a, and anti-GQ1b antibodies are associated with
    specific clinical subtypes.
  biological_processes:
  - preferred_term: Immunoglobulin Production
    term:
      id: GO:0002377
      label: immunoglobulin production
  evidence:
  - reference: PMID:24000328
    reference_title: "Role of Campylobacter jejuni infection in the pathogenesis of Guillain-Barré syndrome: an update."
    supports: SUPPORT
    snippet: >-
      Molecular mimicry between sialylated lipooligosaccharide structures on the cell
      envelope of these bacteria and ganglioside epitopes on the human nerves that
      generates cross-reactive immune response results in autoimmune-driven nerve
      damage.
    explanation: >-
      Demonstrates the molecular mimicry mechanism where C. jejuni lipooligosaccharides
      resemble nerve gangliosides, leading to cross-reactive antibodies that attack
      peripheral nerves.
  - reference: PMID:37108447
    reference_title: "Immune-Mediated Neuropathies: Pathophysiology and Management."
    supports: SUPPORT
    snippet: >-
      The presence of specific anti-glycoconjugate antibodies indicates an underlying
      process of molecular mimicry and sometimes assists in the classification of
      these
      disorders.
    explanation: >-
      Confirms that anti-ganglioside antibodies in GBS result from molecular mimicry
      and help classify disease subtypes.
- name: Complement-Mediated Nerve Damage
  description: >-
    Antibody binding activates complement cascade, leading to membrane attack
    complex deposition on Schwann cells and nodes of Ranvier. This causes
    demyelination in AIDP or axonal damage in AMAN/AMSAN variants.
  cell_types:
  - preferred_term: Schwann Cell
    term:
      id: CL:0002573
      label: Schwann cell
  biological_processes:
  - preferred_term: Complement Activation
    term:
      id: GO:0006956
      label: complement activation
  evidence:
  - reference: PMID:10355667
    reference_title: "Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro."
    supports: PARTIAL
    snippet: >-
      These data indicate that anti-ganglioside antibodies can diffuse into a
      desheathed nerve, bind to nodes of Ranvier and fix complement in vitro without
      resulting in any overt physiological deterioration of the nerve over 4-6 h.
    explanation: >-
      Demonstrates that anti-ganglioside antibodies bind nodes of Ranvier and activate
      complement cascade, establishing the complement-mediated mechanism of nerve
      damage.
  - reference: PMID:8619548
    reference_title: "Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy."
    supports: SUPPORT
    snippet: >-
      Many fibers had a rim of the complement activation marker C3d and the terminal
      complement complex neoantigen C5b-9 along the outer surface of the Schwann cells.
    explanation: >-
      Immunocytochemistry evidence showing C3d and C5b-9 membrane attack complex deposition
      on Schwann cell surfaces in AIDP, confirming complement-mediated pathology.
- name: Macrophage-Mediated Demyelination
  description: >-
    In AIDP, macrophages infiltrate peripheral nerves and strip myelin from
    axons. T cells may also contribute to the inflammatory milieu and
    tissue damage.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:37108447
    reference_title: "Immune-Mediated Neuropathies: Pathophysiology and Management."
    supports: SUPPORT
    snippet: >-
      The immunological mechanisms, which include macrophage infiltration, inflammation
      and proliferation of Schwann cells, result in variable degrees of demyelination
      and axonal degeneration.
    explanation: >-
      Describes macrophage infiltration as a key immunological mechanism leading to
      demyelination and axonal degeneration in immune-mediated neuropathies including
      GBS.
  - reference: PMID:8619548
    reference_title: "Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy."
    supports: SUPPORT
    snippet: >-
      Vesicular degeneration was seen before the invasion of macrophages into the
      myelin,
      and was the predominant change in the subject with symptoms for 3 days.
    explanation: >-
      Shows the temporal sequence of pathology in AIDP, with macrophage invasion into
      myelin following initial complement-mediated damage.
- name: Seronegative and Alternative Immune Mechanisms in Anti-GQ1b Syndromes
  description: >-
    The anti-GQ1b antibody syndrome spectrum encompasses Bickerstaff Brainstem
    Encephalitis (BBE), Miller Fisher Syndrome (MFS), and related disorders.
    Approximately one-third of clinically defined BBE cases are seronegative for
    anti-GQ1b antibodies, indicating alternative immune pathways beyond the
    canonical anti-GQ1b IgG-mediated complement-dependent pathway. Seronegative
    cases suggest additional mechanisms driving complement-mediated damage to
    ganglioside-rich neural structures.
  biological_processes:
  - preferred_term: Complement Activation
    term:
      id: GO:0006956
      label: complement activation
  downstream:
  - target: Complement-Mediated Nerve Damage
  evidence:
  - reference: PMID:42093930
    reference_title: "A unified spectrum model for the anti-GQ1b antibody syndromes: from pathophysiology to a new diagnostic framework."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Approximately one-third of clinically defined BBE cases are seronegative,
      suggesting alternative mechanisms.
    explanation: >-
      The review identifies seronegative BBE as a key gap in understanding the
      anti-GQ1b antibody syndrome spectrum, highlighting that mechanisms beyond
      anti-GQ1b IgG antibodies drive some BBE cases.
  - reference: PMID:42093930
    reference_title: "A unified spectrum model for the anti-GQ1b antibody syndromes: from pathophysiology to a new diagnostic framework."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pathogenesis is primarily driven by anti-GQ1b IgG antibodies, generated following
      infection via molecular mimicry, which trigger complement-mediated damage to
      ganglioside-rich neural structures. The clinical presentation ranges from purely
      peripheral deficits (MFS) to severe central nervous system dysfunction (BBE), with
      frequent BBE-GBS overlap syndromes.
    explanation: >-
      Confirms the spectrum nature of anti-GQ1b syndromes and establishes that
      complement-mediated damage is a unifying mechanism across the spectrum,
      suggesting that seronegative cases may involve alternative triggers of
      the same complement-dependent pathway.
phenotypes:
- name: Areflexia
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Areflexia
    term:
      id: HP:0001284
      label: Areflexia
  notes: Universal finding
  evidence:
  - reference: PMID:33603872
    reference_title: "Therapeutic plasma exchange as a first-choice therapy for axonal Guillain-Barré syndrome: A case-based review of the literature (Review)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GBS affects the peripheral nervous system and is characterized by progressive
      motor deficit in the limbs with ascending sensory deficits, involvement of
      muscles innervated by the cranial nerves, reduction or abolition of the
      deep tendon reflexes, and possible impairment of the autonomic nervous system
    explanation: >-
      The review explicitly describes reduction or abolition of deep tendon reflexes
      as part of the GBS clinical syndrome.
- name: Limb Weakness
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Limb Muscle Weakness
    term:
      id: HP:0003690
      label: Limb muscle weakness
  notes: Ascending, symmetric
  evidence:
  - reference: PMID:33603872
    reference_title: "Therapeutic plasma exchange as a first-choice therapy for axonal Guillain-Barré syndrome: A case-based review of the literature (Review)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Guillain-Barré syndrome is an acute immune-mediated disease that affects the
      peripheral nervous system, with progressive motor deficit in the limbs
    explanation: >-
      Progressive motor deficit in the limbs supports limb weakness as a core
      GBS phenotype.
- name: Respiratory Failure
  category: Respiratory
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Respiratory Insufficiency
    term:
      id: HP:0002093
      label: Respiratory insufficiency
  notes: May require mechanical ventilation
  evidence:
  - reference: DOI:10.1038/s41582-019-0250-9
    reference_title: "Diagnosis and management of Guillain–Barré syndrome in ten steps"
    supports: SUPPORT
    snippet: >-
      The ten steps then cover early recognition and diagnosis of GBS, admission
      to the intensive care unit, treatment indication and selection, monitoring
      and treatment of disease progression, prediction of clinical course and
      outcome, and management of complications and sequelae.
    explanation: >-
      The guideline includes ICU admission and monitoring for disease progression,
      consistent with the need to detect and manage respiratory failure in severe
      GBS.
- name: Autonomic Dysfunction
  category: Neurological
  frequency: FREQUENT
  notes: Includes urinary retention and other autonomic impairment, especially in axonal variants.
  phenotype_term:
    preferred_term: Autonomic dysfunction
    term:
      id: HP:0012332
      label: Abnormal autonomic nervous system physiology
  evidence:
  - reference: PMID:33603872
    reference_title: "Therapeutic plasma exchange as a first-choice therapy for axonal Guillain-Barré syndrome: A case-based review of the literature (Review)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autonomic impairment is common in GBS, especially in cases where
      respiratory dysfunction is present, as happened with our patient (2).
      Urinary dysfunction is one manifestation and has been reported in 50% of
      patients with axonal GBS, more frequently than in classic GBS (21%), but
      the underlying mechanism is not well known and is believed to be either
      bladder areflexia or a non-relaxing urethral sphincter (43,48,49).
    explanation: >-
      The review documents common autonomic impairment in GBS and quantifies
      urinary dysfunction in axonal and classic GBS, supporting an autonomic
      dysfunction phenotype.
- name: Paresthesia
  category: Neurological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Paresthesia
    term:
      id: HP:0003401
      label: Paresthesia
  notes: Sensory symptoms often precede weakness
  evidence:
  - reference: DOI:10.3389/fneur.2024.1368706
    reference_title: "Guillain-Barré syndrome after surgery: a literature review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Postoperative sedation, intubation, and restraint use make the diagnosis
      of GBS difficult, as the onset of symptoms of weakness or numbness in
      those contexts are not obvious.
    explanation: >-
      The review identifies numbness as a presenting sensory symptom that can
      accompany GBS weakness.
- name: "Distal sensory impairment"
  category: Neurologic
  description: "Sensory abnormalities, typically distal, accompany the acute ascending weakness of Guillain-Barré syndrome."
  phenotype_term:
    preferred_term: "Distal sensory impairment"
    term:
      id: HP:0002936
      label: "Distal sensory impairment"
  evidence:
  - reference: PMID:39058828
    reference_title: "Clinical presentation and symptomatology of Guillain-Barré syndrome: A literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "acute onset ascending paralysis and sensory abnormalities"
    explanation: "This review characterizes GBS by acute onset ascending paralysis and sensory abnormalities."
- name: "Cranial nerve involvement"
  category: Neurologic
  description: "Cranial nerve involvement (e.g., facial weakness, bulbar palsy) is a frequent feature of Guillain-Barré syndrome."
  phenotype_term:
    preferred_term: "Cranial nerve involvement"
    term:
      id: HP:0006824
      label: "Cranial nerve paralysis"
  evidence:
  - reference: PMID:37814552
    reference_title: "European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients may have cranial nerve involvement, respiratory insufficiency, autonomic dysfunction and pain"
    explanation: "The EAN/PNS guideline lists cranial nerve involvement among GBS features."
- name: "Pain"
  category: Neurologic
  description: "Pain is a common symptom of Guillain-Barré syndrome, often neuropathic and requiring analgesia."
  phenotype_term:
    preferred_term: "Pain"
    term:
      id: HP:0012531
      label: "Pain"
  evidence:
  - reference: PMID:37814552
    reference_title: "European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients may have cranial nerve involvement, respiratory insufficiency, autonomic dysfunction and pain"
    explanation: "The EAN/PNS guideline lists pain among GBS features."
biochemical:
- name: CSF Protein
  presence: Elevated
  context: Albuminocytologic dissociation characteristic
  evidence:
  - reference: PMID:37076309
    reference_title: "CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Albuminocytologic dissociation (ACD) was defined as an increased protein
      level (>0.45 g/L) in the absence of elevated white cell count (<50 cells/μL).
    explanation: >-
      This large IGOS CSF study defines albuminocytologic dissociation as elevated
      CSF protein without elevated white-cell count, matching the modeled
      biochemical finding.
- name: Neurofilament Light Chain
  presence: Elevated
  context: Plasma and CSF axonal injury biomarker in immune-mediated neuropathy
  evidence:
  - reference: DOI:10.69622/28457924.v1
    reference_title: Biomarker and pathogenic study of immune-mediated neuropathies
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In GBS, CIDP, and PDN, levels of NfL were elevated in both plasma and CSF,
      whereas in patients with MMN the levels of NfL were elevated only in
      plasma.
    explanation: >-
      The biomarker study supports neurofilament light chain elevation as a separate
      GBS-associated biomarker rather than as evidence for total CSF protein.
- name: Antiganglioside Antibodies
  presence: Variable
  context: GM1, GD1a, GQ1b depending on subtype
  evidence:
  - reference: DOI:10.1186/s43161-024-00258-8
    reference_title: "Autoimmune mechanisms in Guillain-Barré syndrome subtypes: a systematic review"
    supports: SUPPORT
    snippet: >-
      Key findings indicate that specific autoantibodies, such as anti-GM1 and
      anti-GQ1b, are associated with distinct subtypes of GBS, contributing to
      the disease’s heterogeneity.
    explanation: >-
      The review directly supports antiganglioside antibody variability across
      GBS subtypes.
environmental:
- name: Campylobacter jejuni Infection
  notes: Most common preceding infection
  evidence:
  - reference: PMID:24000328
    reference_title: "Role of Campylobacter jejuni infection in the pathogenesis of Guillain-Barré syndrome: an update."
    supports: SUPPORT
    snippet: >-
      Thus, C. jejuni is now considered as a major triggering agent of GBS. Molecular
      mimicry between sialylated lipooligosaccharide structures on the cell envelope
      of these bacteria and ganglioside epitopes on the human nerves that generates
      cross-reactive immune response results in autoimmune-driven nerve damage.
    explanation: >-
      Establishes C. jejuni as the major triggering infection for GBS through molecular
      mimicry mechanism between bacterial lipooligosaccharides and nerve gangliosides.
- name: Cytomegalovirus Infection
  notes: Associated with sensory GBS
  evidence:
  - reference: PMID:33603872
    reference_title: "Therapeutic plasma exchange as a first-choice therapy for axonal Guillain-Barré syndrome: A case-based review of the literature (Review)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most frequent pathogens involved are C. jejuni, cytomegalovirus (CMV),
      Epstein-Barr virus (EBV), Zika, post-flu or other events involving
      immunization with vaccines such as rabies vaccines (27,28), surgery and
      anesthesia (5).
    explanation: >-
      The review identifies cytomegalovirus as a major antecedent infection in
      GBS.
- name: Zika Virus Infection
  notes: Associated with outbreaks
  evidence:
  - reference: DOI:10.1038/s41582-019-0250-9
    reference_title: "Diagnosis and management of Guillain–Barré syndrome in ten steps"
    supports: SUPPORT
    snippet: >-
      The incidence of GBS can therefore increase during outbreaks of infectious
      diseases, as was seen during the Zika virus epidemics in 2013 in French
      Polynesia and 2015 in Latin America.
    explanation: >-
      This guideline review links Zika outbreaks with increased GBS incidence.
treatments:
- name: IVIG
  description: First-line immunotherapy, equally effective as plasmapheresis.
  evidence:
  - reference: PMID:17217855
    reference_title: Guillain-barré syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Meta-analyses show efficacy of plasmapheresis and immunoglobulin therapy,
      but not corticosteroids, in hastening recovery.
    explanation: >-
      The review summarizes meta-analysis evidence supporting immunoglobulin
      therapy for GBS recovery.
  target_mechanisms:
  - target: Molecular Mimicry and Antiganglioside Antibodies
    treatment_effect: INHIBITS
    description: >-
      IVIG saturates Fc receptors, neutralizes complement activation, and
      modulates antiganglioside antibody function, reducing antibody-mediated
      damage to peripheral nerve myelin and axonal membranes.
  - target: Complement-Mediated Nerve Damage
    treatment_effect: INHIBITS
    description: >-
      IVIG inhibits complement activation pathways and blocks MAC formation,
      limiting complement-driven destruction of Schwann cell membranes and
      nodes of Ranvier.
- name: Plasmapheresis
  description: Removes pathogenic antibodies; alternative to IVIG.
  evidence:
  - reference: PMID:17217855
    reference_title: Guillain-barré syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Meta-analyses show efficacy of plasmapheresis and immunoglobulin therapy,
      but not corticosteroids, in hastening recovery.
    explanation: >-
      The review explicitly names plasmapheresis as an evidence-supported GBS
      treatment.
  target_mechanisms:
  - target: Molecular Mimicry and Antiganglioside Antibodies
    treatment_effect: INHIBITS
    description: >-
      Plasmapheresis physically removes circulating antiganglioside antibodies
      (anti-GM1, anti-GD1b, anti-GQ1b) from the blood, acutely reducing the
      antibody burden targeting peripheral nerve components.
- name: Supportive Care
  description: ICU monitoring, mechanical ventilation if needed.
  evidence:
  - reference: DOI:10.1038/s41582-019-0250-9
    reference_title: "Diagnosis and management of Guillain–Barré syndrome in ten steps"
    supports: SUPPORT
    snippet: >-
      The ten steps then cover early recognition and diagnosis of GBS, admission
      to the intensive care unit, treatment indication and selection, monitoring
      and treatment of disease progression, prediction of clinical course and
      outcome, and management of complications and sequelae.
    explanation: >-
      ICU admission, monitoring, and complication management support the modeled
      supportive-care treatment entry.
- name: Physical Therapy
  description: Rehabilitation during recovery phase.
  evidence:
  - reference: PMID:25402491
    reference_title: "Functional outcomes and efficiency of rehabilitation in a national cohort of patients with Guillain-Barré syndrome and other inflammatory polyneuropathies."
    supports: SUPPORT
    snippet: >-
      Patients with polyneuropathies have both physical and cognitive
      disabilities that are amenable to change with rehabilitation, resulting in
      significant reduction in on-going care-costs, especially for highly
      dependent patients.
    explanation: >-
      The rehabilitation cohort supports physical therapy and rehabilitation as
      part of GBS recovery care.
- name: Eculizumab
  description: >-
    Investigational complement C5 inhibitor add-on to IVIG evaluated in severe
    GBS; the phase 3 trial did not meet its primary efficacy endpoint.
  treatment_term:
    preferred_term: complement 5 inhibitor agent therapy
    term:
      id: MAXO:0001483
      label: complement 5 inhibitor agent therapy
    therapeutic_agent:
    - preferred_term: Eculizumab
      term:
        id: NCIT:C48386
        label: Eculizumab
  target_phenotypes:
  - preferred_term: Limb muscle weakness
    term:
      id: HP:0003690
      label: Limb muscle weakness
  evidence:
  - reference: DOI:10.1111/jns.12646
    reference_title: "Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial"
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although well tolerated, eculizumab treatment did not show significant
      effects on motor function recovery compared to placebo in patients with GBS.
    explanation: >-
      The phase 3 trial supports eculizumab as a studied complement-directed
      therapy in severe GBS, while showing no significant motor recovery benefit.
  target_mechanisms:
  - target: Complement-Mediated Nerve Damage
    treatment_effect: INHIBITS
    description: >-
      Eculizumab blocks complement C5 cleavage, preventing MAC assembly at the
      node of Ranvier and paranodal membrane, the primary target of
      complement-mediated axonal injury in the AMAN and AMSAN subtypes of GBS.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    evidence:
    - reference: DOI:10.1038/s41582-019-0250-9
      reference_title: "Diagnosis and management of Guillain–Barré syndrome in ten steps"
      supports: SUPPORT
      snippet: >-
        Guillain–Barré syndrome (GBS) is a rare, but potentially fatal,
        immune-mediated disease of the peripheral nerves and nerve roots that is
        usually triggered by infections.
      explanation: >-
        Peripheral nerve and nerve-root involvement supports neurological classification.
  - classification_value: IMMUNE_RHEUMATOLOGIC
    evidence:
    - reference: DOI:10.1186/s43161-024-00258-8
      reference_title: "Autoimmune mechanisms in Guillain-Barré syndrome subtypes: a systematic review"
      supports: SUPPORT
      snippet: >-
        Guillain-Barré syndrome (GBS) is a complex autoimmune disorder
        characterized by acute onset of motor weakness, often following an
        infectious illness.
      explanation: >-
        The systematic review explicitly characterizes GBS as autoimmune.
clinical_trials:
- name: NCT04752566
  phase: PHASE_III
  status: COMPLETED
  description: >-
    Phase 3 multicenter, double-blind, randomized, placebo-controlled trial of
    eculizumab add-on therapy to IVIG in severe Guillain-Barre syndrome; the
    primary endpoint was not achieved.
  target_phenotypes:
  - preferred_term: Limb muscle weakness
    term:
      id: HP:0003690
      label: Limb muscle weakness
  evidence:
  - reference: clinicaltrials:NCT04752566
    reference_title: "A Phase 3, Prospective, Multicenter, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Eculizumab in Patients With Guillain-Barré Syndrome (GBS)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is a Phase 3, prospective, multicenter, placebo controlled, double
      blind, randomized study to investigate the efficacy and safety of
      eculizumab in participants with severe GBS
    explanation: >-
      The ClinicalTrials.gov summary supports the existence and design of the
      phase 3 eculizumab trial in severe GBS.
  - reference: DOI:10.1111/jns.12646
    reference_title: "Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial"
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primary endpoint was not achieved (hazard ratio, 0.9; 95% CI,
      0.45–1.97; p = .89).
    explanation: >-
      The published phase 3 report is relevant to severe GBS treatment but did
      not demonstrate statistically significant primary efficacy.
references:
- reference: DOI:10.1007/s00415-024-12186-7
  title: 'Guillain–Barré syndrome and COVID-19 vaccination: a systematic review and meta-analysis'
  found_in:
  - Guillain_Barre_Syndrome-deep-research-cyberian-codex.md
  - Guillain_Barre_Syndrome-deep-research-falcon.md
  findings: []
- reference: DOI:10.1038/s41598-024-74729-2
  title: Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023
  found_in:
  - Guillain_Barre_Syndrome-deep-research-cyberian-codex.md
  - Guillain_Barre_Syndrome-deep-research-falcon.md
  findings: []
- reference: DOI:10.1093/brain/awac418
  title: Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage
  found_in:
  - Guillain_Barre_Syndrome-deep-research-cyberian-codex.md
  - Guillain_Barre_Syndrome-deep-research-falcon.md
  findings: []
- reference: DOI:10.1111/jns.12625
  title: 'Conduction slowing, conduction block and temporal dispersion in demyelinating, dysmyelinating and axonal neuropathies: Electrophysiology meets pathology'
  found_in:
  - Guillain_Barre_Syndrome-deep-research-cyberian-codex.md
  - Guillain_Barre_Syndrome-deep-research-falcon.md
  findings: []
- reference: DOI:10.1186/s43161-024-00258-8
  title: 'Autoimmune mechanisms in Guillain-Barré syndrome subtypes: a systematic review'
  found_in:
  - Guillain_Barre_Syndrome-deep-research-cyberian-codex.md
  - Guillain_Barre_Syndrome-deep-research-falcon.md
  findings: []
- reference: DOI:10.3389/fimmu.2024.1415986
  title: 'Variation in worldwide incidence of Guillain-Barré syndrome: a population-based study in urban China and existing global evidence'
  found_in:
  - Guillain_Barre_Syndrome-deep-research-cyberian-codex.md
  - Guillain_Barre_Syndrome-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/ijms24087288
  title: 'Immune-Mediated Neuropathies: Pathophysiology and Management'
  found_in:
  - Guillain_Barre_Syndrome-deep-research-cyberian-codex.md
  - Guillain_Barre_Syndrome-deep-research-falcon.md
  findings: []
- reference: DOI:10.69622/28457924.v1
  title: Biomarker and pathogenic study of immune-mediated neuropathies
  found_in:
  - Guillain_Barre_Syndrome-deep-research-cyberian-codex.md
  - Guillain_Barre_Syndrome-deep-research-falcon.md
  findings: []
- reference: DOI:10.3389/fneur.2024.1368706
  title: "Guillain-Barré syndrome after surgery: a literature review"
  findings: []
- reference: DOI:10.1111/jns.12646
  title: "Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial"
  findings: []
- reference: PMID:17217855
  title: Guillain-barré syndrome.
  findings: []
- reference: PMID:33603872
  title: "Therapeutic plasma exchange as a first-choice therapy for axonal Guillain-Barré syndrome: A case-based review of the literature (Review)."
  findings: []
- reference: PMID:37076309
  title: "CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome."
  findings: []
- reference: clinicaltrials:NCT04752566
  title: "A Phase 3, Prospective, Multicenter, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Eculizumab in Patients With Guillain-Barré Syndrome (GBS)"
  findings: []
📚

References & Deep Research

References

14
DOI:10.1007/s00415-024-12186-7
Guillain–Barré syndrome and COVID-19 vaccination: a systematic review and meta-analysis
No top-level findings curated for this source.
DOI:10.1038/s41598-024-74729-2
Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023
No top-level findings curated for this source.
DOI:10.1093/brain/awac418
Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage
No top-level findings curated for this source.
DOI:10.1111/jns.12625
Conduction slowing, conduction block and temporal dispersion in demyelinating, dysmyelinating and axonal neuropathies: Electrophysiology meets pathology
No top-level findings curated for this source.
DOI:10.1186/s43161-024-00258-8
Autoimmune mechanisms in Guillain-Barré syndrome subtypes: a systematic review
No top-level findings curated for this source.
DOI:10.3389/fimmu.2024.1415986
Variation in worldwide incidence of Guillain-Barré syndrome: a population-based study in urban China and existing global evidence
No top-level findings curated for this source.
DOI:10.3390/ijms24087288
Immune-Mediated Neuropathies: Pathophysiology and Management
No top-level findings curated for this source.
DOI:10.69622/28457924.v1
Biomarker and pathogenic study of immune-mediated neuropathies
No top-level findings curated for this source.
DOI:10.3389/fneur.2024.1368706
Guillain-Barré syndrome after surgery: a literature review
No top-level findings curated for this source.
DOI:10.1111/jns.12646
Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial
No top-level findings curated for this source.
PMID:17217855
Guillain-barré syndrome.
No top-level findings curated for this source.
PMID:33603872
Therapeutic plasma exchange as a first-choice therapy for axonal Guillain-Barré syndrome: A case-based review of the literature (Review).
No top-level findings curated for this source.
PMID:37076309
CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome.
No top-level findings curated for this source.
clinicaltrials:NCT04752566
A Phase 3, Prospective, Multicenter, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Eculizumab in Patients With Guillain-Barré Syndrome (GBS)
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Guillain-Barre Syndrome
  • Category: Autoimmune
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 15

Key Pathophysiology Nodes

  • Molecular Mimicry and Antiganglioside Antibodies
  • Complement-Mediated Nerve Damage
  • Macrophage-Mediated Demyelination
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1007/s00415-024-12186-7
  • DOI:10.1038/s41598-024-74729-2
  • DOI:10.1093/brain/awac418
  • DOI:10.1111/jns.12625
  • DOI:10.1186/s43161-024-00258-8
  • DOI:10.3389/fimmu.2024.1415986
  • DOI:10.3390/ijms24087288
  • DOI:10.69622/28457924.v1
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 25 citations 2025-12-18T09:56:41.751161

Disease Pathophysiology Research Report

Target Disease

  • Disease Name: Guillain-Barre Syndrome (GBS)
  • MONDO ID: Not specified in retrieved sources
  • Category: Autoimmune

Pathophysiology Overview (narrative)

Guillain-Barre syndrome is an acute, frequently post-infectious, immune-mediated polyradiculoneuropathy in which humoral and cellular immunity target peripheral nerve axolemma and/or myelin, particularly at the node of Ranvier and paranodes. A central paradigm is molecular mimicry: antecedent infections (classically Campylobacter jejuni) elicit anti-glycolipid antibodies that cross-react with nerve gangliosides (GM1, GD1a, GQ1b) concentrated at nodes and motor terminals. Antibody binding initiates classical complement activation (C1q→C3→C5b-9), causing disruption of sodium-channel clusters, paranodal detachment, conduction failure, and varying degrees of axonal degeneration. In parallel, macrophage-mediated segmental demyelination characterizes many AIDP cases, while autoimmunity against nodal/paranodal adhesion proteins (neurofascin, contactin-1, CASPR1) produces a “nodo-paranodopathy” with conduction failure that may be complement-dependent (IgG1/3) or complement-sparing (IgG4). Systemic and endoneurial immune signatures include activated monocytes/macrophages, CD8 T cells, Th17/Treg imbalance, and elevated cytokines (e.g., IL-6, IL-8); CSF albuminocytologic dissociation and neurofilament light (NfL) elevations reflect barrier dysfunction and axonal injury. Recent work and clinical trials have focused on complement inhibition to prevent MAC-mediated nerve injury. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, shastri2023immunemediatedneuropathiespathophysiology pages 8-9)

Category Entity (HGNC/CHEBI where applicable) Role / Mechanism Cellular / Anatomical context Key process (GO-style) Evidence
Autoantibodies Anti-ganglioside Ab (GM1, GD1a, GQ1b) Molecular mimicry → bind axolemma/nodes; fix complement causing nodal disruption Axolemma / nodes of Ranvier; motor terminals antibody-mediated complement activation; disruption of sodium-channel clusters (shastri2023immunemediatedneuropathiespathophysiology pages 8-9, shastri2023immunemediatedneuropathiespathophysiology pages 22-24, oshomoji2024autoimmunemechanismsin pages 7-8)
Complement system C1q; C3; C5b-9 (MAC) Classical pathway activation by IgG/IgM → MAC deposition → axonal/nodal injury Nodes of Ranvier; motor nerve terminals; Schwann cell surfaces classical complement activation; membrane attack complex formation (shastri2023immunemediatedneuropathiespathophysiology pages 8-9, shastri2023immunemediatedneuropathiespathophysiology pages 22-24, NCT04752566)
Nodal adhesion NFASC / NF155 (HGNC: NFASC) Paranodal adhesion; target of autoantibodies causing paranodal dissection and conduction failure Paranode / node of Ranvier node of Ranvier organization; axo-glial adhesion disruption (shastri2023immunemediatedneuropathiespathophysiology pages 7-8, shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
Paranodal protein CNTN1 (contactin-1) Axoglial adhesion molecule; autoantibody target in autoimmune nodopathy Paranode / Schwann cell-axon junction maintenance of paranodal junctions; disruption → nodo-paranodopathy (shastri2023immunemediatedneuropathiespathophysiology pages 7-8, shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
Paranodal protein CASPR1 / CNTNAP1 Partners with contactin-1 in paranodal complex; targeted in nodopathies Paranode / juxtaparanode paranodal junction assembly / stability (shastri2023immunemediatedneuropathiespathophysiology pages 7-8, shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
Innate immune cell Macrophages Mediate segmental demyelination via myelin phagocytosis and inflammatory mediators Endoneurium; Schwann cell–myelin sheaths macrophage-mediated myelin phagocytosis; inflammatory demyelination (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, shastri2023immunemediatedneuropathiespathophysiology pages 8-9)
Innate immune cell Monocytes / intermediate monocytes Circulating inflammatory cells with proinflammatory transcriptomic signatures; recruit/activate endoneurial cells Peripheral blood → endoneurial infiltration leukocyte activation and recruitment; cytokine production (kmezic2025biomarkerandpathogenic pages 137-139, shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
Adaptive immune cell CD8+ T cells Proliferative/activated cytotoxic phenotype; may express axon-guidance genes in early disease Peripheral blood / possible endoneurial presence cytotoxic T cell activation; cell-mediated cytotoxicity (kmezic2025biomarkerandpathogenic pages 137-139, shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
Adaptive immune balance Th17 / Treg imbalance Skewed helper/regulatory T-cell responses contributing to uncontrolled inflammation Peripheral immune compartment; draining nodes T-cell differentiation; dysregulated immune regulation (kmezic2025biomarkerandpathogenic pages 137-139, shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
Humoral immunity B cells / plasma cells Source of pathogenic IgG (anti-ganglioside, anti-nodal) driving complement or IgG-subclass effects Systemic circulation; CSF antibody production and affinity maturation (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, shastri2023immunemediatedneuropathiespathophysiology pages 8-9)
Cytokine IL-6 Proinflammatory cytokine elevated in acute disease; promotes systemic inflammation Blood and CSF; leukocyte–Schwann cell signaling cytokine-mediated signaling pathway (kmezic2025biomarkerandpathogenic pages 137-139, shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
Chemokine / biomarker IL-8 (CXCL8) CSF biomarker validated in GBS/CIDP cohorts; indicates intrathecal inflammation Cerebrospinal fluid; endoneurial inflammatory milieu chemokine-mediated immune cell recruitment; inflammatory signaling (kmezic2025biomarkerandpathogenic pages 137-139, shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
Cytokine Oncostatin M (OSM) Predicted leukocyte–nerve ligand promoting angiogenesis and inflammation in transcriptomic interactomes Leukocyte–Schwann cell interactions; peripheral nerve microenvironment cytokine-mediated cellular response and tissue remodeling (kmezic2025biomarkerandpathogenic pages 137-139, shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
Biomarker Neurofilament light (NfL) Marker of axonal damage; serum/CSF levels rise with axonal injury severity Serum and CSF reflecting peripheral axonal degeneration biomarker of axonal degeneration / neurofilament release (shastri2023immunemediatedneuropathiespathophysiology pages 7-8, kmezic2025biomarkerandpathogenic pages 137-139, shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
Therapeutic Eculizumab (C5 inhibitor) Terminal complement blockade evaluated in Phase 3 trial to prevent MAC-mediated nerve injury Systemic complement inhibition to reduce peripheral nerve complement activity therapeutic inhibition of complement-mediated cytotoxicity (NCT04752566, shastri2023immunemediatedneuropathiespathophysiology pages 8-9, censi2024guillain–barrésyndromeand pages 5-8)

Table: Concise table mapping major molecules, cells, anatomical sites, processes (GO-style) and key evidence IDs supporting Guillain-Barré syndrome pathophysiology; useful as a citable reference for knowledge-base annotation and mechanistic summaries.

1. Core Pathophysiology

  • Molecular mimicry and anti-ganglioside antibodies: Campylobacter jejuni lipooligosaccharides share epitopes with gangliosides; anti-GM1/GD1a localize to nodes/axolemma and motor terminals, triggering complement-mediated disruption of nodal sodium-channel clusters and axonal injury; anti-GQ1b defines Miller Fisher syndrome and related variants. (Quotes/examples: anti-ganglioside antibodies “bind at the node of Ranvier and activate complement, producing… MAC deposition” and “disruption of sodium channel clusters” in experimental models) (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, shastri2023immunemediatedneuropathiespathophysiology pages 8-9, shastri2023immunemediatedneuropathiespathophysiology pages 7-8, oshomoji2024autoimmunemechanismsin pages 7-8)
  • Complement activation: Classical complement pathway is activated by bound IgG/IgM; deposition of C3 and terminal C5b-9 at nodes/terminals precedes myelin degradation and conduction block; complement inhibition in animal models prevents sodium-channel cluster disruption and nerve-terminal injury. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, shastri2023immunemediatedneuropathiespathophysiology pages 8-9)
  • Macrophage-mediated demyelination vs nodo-paranodal autoimmunity: AIDP shows macrophage myelin phagocytosis; nodopathies involve antibodies to neurofascins, contactin-1, CASPR1 with paranodal dissection and conduction failure. IgG subclasses modulate complement involvement (e.g., IgG3/IgG1 complement binding vs IgG4 complement-sparing). (shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
  • Blood–nerve barrier and leukocyte signatures: Early GBS cohorts show activated monocytes and CD8 T cells, Th17/Treg imbalance, and predicted leukocyte–nerve ligand pairs including IL-6, IL-8, and oncostatin M. CSF IL-8 is a validated biomarker in immune-mediated neuropathies. (kmezic2025biomarkerandpathogenic pages 137-139, shastri2023immunemediatedneuropathiespathophysiology pages 22-24)

2. Key Molecular Players

  • Genes/Proteins (HGNC): NFASC (neurofascin; NF155), CNTN1 (contactin-1), CNTNAP1 (CASPR1); complement components C1q, C3, C5b-9; ion channels at nodes (Nav clusters); adhesion complexes at paranodes. Evidence links anti-pan-neurofascin antibodies with complement activation and nodo-paranodal injury. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
  • Chemical entities (CHEBI classes/examples): Gangliosides GM1, GD1a, GQ1b as antibody targets; therapeutic complement inhibitors (e.g., eculizumab) targeting C5. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, NCT04752566)
  • Cell types (CL): Schwann cells; macrophages (segmental demyelination); monocytes; CD8+ T cells; B cells/plasma cells; Th17/Treg subsets; sensory and motor neurons. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, kmezic2025biomarkerandpathogenic pages 137-139)
  • Anatomical locations (UBERON): Peripheral nerve; node of Ranvier; paranode/juxtaparanode; neuromuscular junction/motor terminal; dorsal root ganglion co-cultures show accessibility of anti-pan-neurofascin to nodes. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24)

3. Biological Processes (GO-style)

  • Complement activation, classical pathway; membrane attack complex assembly; antibody-mediated immunity; axo-glial adhesion and node of Ranvier organization; macrophage-mediated myelin phagocytosis; leukocyte activation and cytokine-mediated signaling (IL-6, IL-8, OSM); regulation of ion-channel clustering at nodes; Wallerian/secondary axonal degeneration and axon regeneration programs. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, shastri2023immunemediatedneuropathiespathophysiology pages 8-9, kmezic2025biomarkerandpathogenic pages 137-139)

4. Cellular Components

  • Node of Ranvier; paranodal junction; axolemma; Schwann cell membrane; endoneurium; extracellular space (complement deposition); neuromuscular junction. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, shastri2023immunemediatedneuropathiespathophysiology pages 8-9)

5. Disease Progression (sequence of events)

  • Trigger: Antecedent infection (often C. jejuni) induces cross-reactive anti-ganglioside antibodies via molecular mimicry. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, oshomoji2024autoimmunemechanismsin pages 7-8)
  • Effector phase: Antibodies bind nodal/paranodal targets (gangliosides or adhesion proteins) → classical complement activation (C1q→C3→C5b-9) and/or Fc-mediated recruitment of macrophages. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, shastri2023immunemediatedneuropathiespathophysiology pages 8-9)
  • Tissue injury: Disruption of sodium-channel clusters; paranodal detachment; segmental demyelination; conduction block/failure; secondary axonal degeneration; biomarker release (NfL). (shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
  • Clinical manifestation: Rapidly progressive weakness, areflexia, sensory symptoms, dysautonomia; phenotype varies by antibody specificities (e.g., AMAN/AMSAN vs AIDP; Miller Fisher with ophthalmoplegia/ataxia/areflexia). (oshomoji2024autoimmunemechanismsin pages 7-8, shastri2023immunemediatedneuropathiespathophysiology pages 7-8)

6. Phenotypic Manifestations and Mechanistic Correlations

  • AMAN/AMSAN: Anti-GM1 and anti-GD1a IgG, nodal complement deposition, axolemmal attack; prominent axonal involvement; worse functional outcomes in some cohorts. (oshomoji2024autoimmunemechanismsin pages 7-8, shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
  • AIDP: Macrophage-mediated segmental demyelination; T cell–driven inflammation; conduction slowing/block and temporal dispersion on NCS. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, xu2024variationinworldwide pages 4-7)
  • Miller Fisher syndrome: Anti-GQ1b IgG, complement-dependent injury at cranial nerve terminals; ophthalmoplegia, ataxia, areflexia; often monophasic and self-limited. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, oshomoji2024autoimmunemechanismsin pages 7-8)

Expert syntheses, recent developments, and statistics

  • Epidemiology (2024): Global pooled incidence 1.12 per 100,000 person-years (95% CI 0.98–1.27); urban China 0.41–0.58 per 100,000 (2013–2017). Higher in males (1.38) than females (0.99); regional variation: West Europe ~1.92; South Asia 1.61; North Europe 1.39; North America 1.38; Australia/New Zealand ~0.54; Southeast Asia 0.63; North Africa 0.69. Incidence correlates with enteric infection burden (P=0.007). URL: https://doi.org/10.3389/fimmu.2024.1415986 (Sep 2024) (xu2024variationinworldwide pages 4-7)
  • Vaccine-associated risk (2023–2024): Meta-analysis of COVID-19 vaccines estimated 1.25 GBS cases per million doses overall; adenovirus-vectored vaccines showed ~2.4× increased risk (and ~7× vs mRNA), whereas mRNA vaccines showed much lower association; risk higher after first dose. URL: https://doi.org/10.1007/s00415-024-12186-7 (Jan 2024) (censi2024guillain–barrésyndromeand pages 5-8). Global pharmacovigilance (VigiBase) disproportionality signals: influenza vaccines ROR ~77.9; Ad5-vectored COVID-19 ROR ~14.9; mRNA COVID-19 ROR ~9.66; mean onset ~5.5 days; associations increase with age. URL: https://doi.org/10.1038/s41598-024-74729-2 (Oct 2024) (jeong2024globalburdenof pages 1-2, jeong2024globalburdenof pages 8-8, jeong2024globalburdenof pages 3-4, jeong2024globalburdenof pages 5-8, jeong2024globalburdenof pages 4-5)
  • Complement therapeutics and trials: Phase 3 eculizumab (C5 inhibitor) trial (Japan) randomized 2:1 eculizumab:placebo, all with IVIg; primary endpoint time to Hughes FG≤1 (Week 24); completed Aug 2022, results posted Feb 9, 2024. URL: https://clinicaltrials.gov/ct2/show/NCT04752566 (NCT04752566). Complement’s centrality across axonal and demyelinating patterns emphasizes rationale for classical-pathway blockade; ongoing programs include C1q inhibition (e.g., ANX005) informed by preclinical efficacy. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
  • Nodo-paranodal antibodies and IgG subclass biology: Anti-pan-neurofascin antibodies produce severe nodo-paranodal pathology with complement-mediated effects linked to IgG3/IgG1, while IgG4-related anti-NF155 in chronic disease is complement-sparing; these mechanisms predict treatment response (e.g., IVIg resistance and benefit from antibody-depleting/anti-CD20 therapies). URL: https://doi.org/10.1093/brain/awac418 (Nov 2023) (shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
  • Electrophysiology–pathology integration (2024): Non-uniform conduction slowing, block, and temporal dispersion can occur in both demyelinating and axonal forms; careful correlation with pathology (macrophage demyelination vs paranodal dissection) refines subtype classification and prognosis. URL: https://doi.org/10.1111/jns.12625 (Apr 2024) (xu2024variationinworldwide pages 4-7)

Evidence items (selected with quotes)

  • “Anti-ganglioside antibodies (GM1, GD1a, GD1b, GQ1b) bind at the node of Ranvier and activate complement… leading to C3/C5 cleavage and MAC deposition with disruption of sodium channel clusters” (review of experimental models and human pathology). URL: https://doi.org/10.3390/ijms24087288 (Apr 2023) (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, shastri2023immunemediatedneuropathiespathophysiology pages 8-9)
  • “Anti-pan-neurofascin… antibodies had access to nodes of Ranvier… impaired paranode formation, destruction of paranodal architecture… subclass IgG3 associated with complement binding and cytotoxic effects in vitro.” URL: https://doi.org/10.1093/brain/awac418 (Nov 2023) (shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
  • “Global pooled incidence of GBS was 1.12 (95% CI 0.98–1.27) per 100,000 person-years… incidence in urban China 0.41–0.58… higher in West Europe and South Asia.” URL: https://doi.org/10.3389/fimmu.2024.1415986 (Sep 2024) (xu2024variationinworldwide pages 4-7)
  • “COVID-19 vaccination meta-analysis: 1.25 cases per million doses; adenovirus-vectored vaccines 2.37-fold increased risk… mRNA vaccines 0.32.” URL: https://doi.org/10.1007/s00415-024-12186-7 (Jan 2024) (censi2024guillain–barrésyndromeand pages 5-8)
  • “VigiBase disproportionality: influenza ROR 77.91; Ad5-vectored COVID-19 14.88; mRNA COVID-19 9.66; mean onset 5.47 days.” URL: https://doi.org/10.1038/s41598-024-74729-2 (Oct 2024) (jeong2024globalburdenof pages 1-2, jeong2024globalburdenof pages 8-8)
  • “Eculizumab Phase 3 in severe GBS; all participants received IVIg; primary endpoint time to FG≤1 up to Week 24; results posted 2024-02-09.” URL: https://clinicaltrials.gov/ct2/show/NCT04752566 (NCT04752566)

Knowledge-base aligned annotations

  • Genes/Proteins (HGNC): NFASC (neurofascin/NF155); CNTN1 (contactin-1); CNTNAP1 (CASPR1); complement components C1q, C3, C5 (terminal MAC). (shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
  • Biological Processes (GO): complement activation, classical pathway; membrane attack complex assembly; axo-glial cell adhesion; node of Ranvier organization; macrophage-mediated myelin phagocytosis; leukocyte activation; cytokine-mediated signaling (IL-6, IL-8); regulation of sodium-channel clustering. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, shastri2023immunemediatedneuropathiespathophysiology pages 8-9)
  • Cellular Components (GO): node of Ranvier; paranodal junction; axolemma; myelin sheath; endoneurial space. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
  • Cell Types (CL): Schwann cell; macrophage; monocyte; CD8+ T cell; Th17/Treg; B cell/plasma cell; sensory/motor neuron. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, kmezic2025biomarkerandpathogenic pages 137-139)
  • Anatomical Locations (UBERON): peripheral nerve; node of Ranvier; neuromuscular junction. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
  • Chemical Entities (CHEBI): gangliosides GM1, GD1a, GQ1b; complement-targeting drugs (e.g., eculizumab). (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, NCT04752566)
  • Phenotypes (HP): acute flaccid paralysis; areflexia; sensory ataxia; ophthalmoplegia (MFS); dysautonomia; respiratory failure (severe cases). (oshomoji2024autoimmunemechanismsin pages 7-8)
  • Biomarkers: CSF albuminocytologic dissociation; serum/CSF neurofilament light (NfL) as axonal injury marker; CSF IL-8 as inflammatory biomarker. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, kmezic2025biomarkerandpathogenic pages 137-139)

Current applications and real-world implementations

  • Diagnostics: Antibody testing supports phenotype stratification—anti-ganglioside assays (GM1, GD1a, GQ1b) for AMAN/AMSAN/MFS; nodo-paranodal antibodies (NF155, CNTN1, CASPR1) for autoimmune nodopathy. CSF IL-8 and NfL show promise for diagnostic/prognostic use; albuminocytologic dissociation remains standard supportive evidence. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, kmezic2025biomarkerandpathogenic pages 137-139)
  • Therapeutics: IVIg and plasma exchange remain standard-of-care; complement inhibition is under clinical evaluation—Phase 3 eculizumab completed in 2022 with results posted in 2024; preclinical/early clinical rationale exists for proximal (C1q) blockade. (NCT04752566, shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
  • Electrophysiology-guided care: Integration of NCS patterns with pathological mechanisms (macrophage demyelination vs paranodal dissection vs axolemmal injury) improves prognosis and treatment selection. (xu2024variationinworldwide pages 4-7)

References with URLs and dates

  • Xu L, et al. Variation in worldwide incidence of GBS. Frontiers in Immunology. Sep 2024. https://doi.org/10.3389/fimmu.2024.1415986 (xu2024variationinworldwide pages 4-7)
  • Censi S, et al. GBS and COVID-19 vaccination meta-analysis. Journal of Neurology. Jan 2024. https://doi.org/10.1007/s00415-024-12186-7 (censi2024guillain–barrésyndromeand pages 5-8)
  • Jeong YD, et al. Global burden of vaccine-associated GBS (VigiBase). Scientific Reports. Oct 2024. https://doi.org/10.1038/s41598-024-74729-2 (jeong2024globalburdenof pages 1-2, jeong2024globalburdenof pages 8-8, jeong2024globalburdenof pages 3-4, jeong2024globalburdenof pages 4-5)
  • Appeltshauser L, et al. Anti-pan-neurofascin antibodies and complement. Brain. Nov 2023. https://doi.org/10.1093/brain/awac418 (shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
  • Uncini A, et al. Conduction slowing/block: electrophysiology meets pathology. J Peripher Nerv Syst. Apr 2024. https://doi.org/10.1111/jns.12625 (xu2024variationinworldwide pages 4-7)
  • Shastri A, et al. Immune-mediated neuropathies: pathophysiology and management. IJMS. Apr 2023. https://doi.org/10.3390/ijms24087288 (mechanistic complement/ganglioside evidence) (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, shastri2023immunemediatedneuropathiespathophysiology pages 8-9, shastri2023immunemediatedneuropathiespathophysiology pages 7-8)
  • Oshomoji OI, et al. Autoimmune mechanisms in GBS subtypes: systematic review. Bulletin of Faculty of Physical Therapy. Dec 2024. https://doi.org/10.1186/s43161-024-00258-8 (oshomoji2024autoimmunemechanismsin pages 7-8)
  • ClinicalTrials.gov. Eculizumab Phase 3 in GBS (NCT04752566). Results posted Feb 9, 2024. https://clinicaltrials.gov/ct2/show/NCT04752566 (NCT04752566)

Appendix: Mapping to requested ontologies

  • Gene/Protein annotations (HGNC): NFASC (neurofascin/NF155); CNTN1; CNTNAP1 (CASPR1); C1QA/C3/C5. Mechanisms: node/paranode adhesion; classical complement activation; MAC assembly; sodium-channel cluster disruption; macrophage myelin phagocytosis. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, shastri2023immunemediatedneuropathiespathophysiology pages 8-9)
  • GO Biological Processes: complement activation (classical pathway); membrane attack complex assembly; axo-glial cell adhesion; node of Ranvier organization; macrophage-mediated myelin phagocytosis; leukocyte activation; cytokine-mediated signaling; regulation of ion-channel clustering. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, shastri2023immunemediatedneuropathiespathophysiology pages 8-9)
  • GO Cellular Components: node of Ranvier; paranode; axolemma; myelin sheath; endoneurial space. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
  • CL Cell Types: Schwann cell; macrophage; monocyte; CD8 T cell; Th17/Treg; B cell; sensory/motor neurons. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, kmezic2025biomarkerandpathogenic pages 137-139)
  • UBERON Anatomy: peripheral nerve; node of Ranvier; neuromuscular junction. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24)
  • CHEBI: gangliosides GM1, GD1a, GQ1b; complement inhibitor drug class (e.g., C5 inhibitor).
  • HP Phenotypes: acute flaccid paralysis; areflexia; ophthalmoplegia; ataxia; sensory loss; autonomic dysfunction. (oshomoji2024autoimmunemechanismsin pages 7-8)

Limitations and open questions: Although strong evidence supports complement-mediated injury in axonal forms and nodopathies, heterogeneity across cohorts suggests overlapping mechanisms in AIDP/axonal subtypes. Large randomized trials of proximal complement inhibition (e.g., C1q) and validated, widely accessible assays for nodo-paranodal antibodies are areas for ongoing research. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24, xu2024variationinworldwide pages 4-7)

References

  1. (shastri2023immunemediatedneuropathiespathophysiology pages 22-24): Abhishek Shastri, Ahmad Al Aiyan, Uday Kishore, and Maria Elena Farrugia. Immune-mediated neuropathies: pathophysiology and management. International Journal of Molecular Sciences, 24:7288, Apr 2023. URL: https://doi.org/10.3390/ijms24087288, doi:10.3390/ijms24087288. This article has 69 citations and is from a poor quality or predatory journal.

  2. (shastri2023immunemediatedneuropathiespathophysiology pages 8-9): Abhishek Shastri, Ahmad Al Aiyan, Uday Kishore, and Maria Elena Farrugia. Immune-mediated neuropathies: pathophysiology and management. International Journal of Molecular Sciences, 24:7288, Apr 2023. URL: https://doi.org/10.3390/ijms24087288, doi:10.3390/ijms24087288. This article has 69 citations and is from a poor quality or predatory journal.

  3. (oshomoji2024autoimmunemechanismsin pages 7-8): Olawale Isreal Oshomoji, J. O. Ajiroba, S. O. Semudara, M. A. Olayemi, and S. O. Adeoye. Autoimmune mechanisms in guillain-barré syndrome subtypes: a systematic review. Bulletin of Faculty of Physical Therapy, Dec 2024. URL: https://doi.org/10.1186/s43161-024-00258-8, doi:10.1186/s43161-024-00258-8. This article has 7 citations and is from a peer-reviewed journal.

  4. (NCT04752566): A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome. Alexion Pharmaceuticals, Inc.. 2021. ClinicalTrials.gov Identifier: NCT04752566

  5. (shastri2023immunemediatedneuropathiespathophysiology pages 7-8): Abhishek Shastri, Ahmad Al Aiyan, Uday Kishore, and Maria Elena Farrugia. Immune-mediated neuropathies: pathophysiology and management. International Journal of Molecular Sciences, 24:7288, Apr 2023. URL: https://doi.org/10.3390/ijms24087288, doi:10.3390/ijms24087288. This article has 69 citations and is from a poor quality or predatory journal.

  6. (kmezic2025biomarkerandpathogenic pages 137-139): Ivan Kmezic. Biomarker and pathogenic study of immune-mediated neuropathies. Apr 2025. URL: https://doi.org/10.69622/28457924.v1, doi:10.69622/28457924.v1.

  7. (censi2024guillain–barrésyndromeand pages 5-8): Stefano Censi, Giandomenico Bisaccia, Sabina Gallina, Valentina Tomassini, and Antonino Uncini. Guillain–barré syndrome and covid-19 vaccination: a systematic review and meta-analysis. Journal of Neurology, 271:1063-1071, Jan 2024. URL: https://doi.org/10.1007/s00415-024-12186-7, doi:10.1007/s00415-024-12186-7. This article has 24 citations and is from a domain leading peer-reviewed journal.

  8. (xu2024variationinworldwide pages 4-7): Lu Xu, Chen Zhao, Yutong Bao, Yuchen Liu, Yuqing Liang, Jiyu Wei, Guozhen Liu, Jinxi Wang, Siyan Zhan, Shengfeng Wang, and Dongsheng Fan. Variation in worldwide incidence of guillain-barré syndrome: a population-based study in urban china and existing global evidence. Frontiers in Immunology, Sep 2024. URL: https://doi.org/10.3389/fimmu.2024.1415986, doi:10.3389/fimmu.2024.1415986. This article has 24 citations and is from a peer-reviewed journal.

  9. (jeong2024globalburdenof pages 1-2): Yi Deun Jeong, Seoyoung Park, Sooji Lee, Woojin Jang, Jaeyu Park, Kyeongmin Lee, Jinseok Lee, Jiseung Kang, Raphael Udeh, Masoud Rahmati, Seung Geun Yeo, Lee Smith, Hayeon Lee, and Dong Keon Yon. Global burden of vaccine-associated guillain-barré syndrome over 170 countries from 1967 to 2023. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-74729-2, doi:10.1038/s41598-024-74729-2. This article has 22 citations and is from a peer-reviewed journal.

  10. (jeong2024globalburdenof pages 8-8): Yi Deun Jeong, Seoyoung Park, Sooji Lee, Woojin Jang, Jaeyu Park, Kyeongmin Lee, Jinseok Lee, Jiseung Kang, Raphael Udeh, Masoud Rahmati, Seung Geun Yeo, Lee Smith, Hayeon Lee, and Dong Keon Yon. Global burden of vaccine-associated guillain-barré syndrome over 170 countries from 1967 to 2023. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-74729-2, doi:10.1038/s41598-024-74729-2. This article has 22 citations and is from a peer-reviewed journal.

  11. (jeong2024globalburdenof pages 3-4): Yi Deun Jeong, Seoyoung Park, Sooji Lee, Woojin Jang, Jaeyu Park, Kyeongmin Lee, Jinseok Lee, Jiseung Kang, Raphael Udeh, Masoud Rahmati, Seung Geun Yeo, Lee Smith, Hayeon Lee, and Dong Keon Yon. Global burden of vaccine-associated guillain-barré syndrome over 170 countries from 1967 to 2023. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-74729-2, doi:10.1038/s41598-024-74729-2. This article has 22 citations and is from a peer-reviewed journal.

  12. (jeong2024globalburdenof pages 5-8): Yi Deun Jeong, Seoyoung Park, Sooji Lee, Woojin Jang, Jaeyu Park, Kyeongmin Lee, Jinseok Lee, Jiseung Kang, Raphael Udeh, Masoud Rahmati, Seung Geun Yeo, Lee Smith, Hayeon Lee, and Dong Keon Yon. Global burden of vaccine-associated guillain-barré syndrome over 170 countries from 1967 to 2023. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-74729-2, doi:10.1038/s41598-024-74729-2. This article has 22 citations and is from a peer-reviewed journal.

  13. (jeong2024globalburdenof pages 4-5): Yi Deun Jeong, Seoyoung Park, Sooji Lee, Woojin Jang, Jaeyu Park, Kyeongmin Lee, Jinseok Lee, Jiseung Kang, Raphael Udeh, Masoud Rahmati, Seung Geun Yeo, Lee Smith, Hayeon Lee, and Dong Keon Yon. Global burden of vaccine-associated guillain-barré syndrome over 170 countries from 1967 to 2023. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-74729-2, doi:10.1038/s41598-024-74729-2. This article has 22 citations and is from a peer-reviewed journal.